Abstracts Archive

Introduction: We engineered a PEGylated polymer nanoparticle (PNP) encapsulating the potent Class 1 HDAC inhibitor romidepsin and demonstrated its superior tolerability and efficacy compared to free romidepsin T-cell lymphoma models. The PNP was optimized with focus on physicochemical propertie...

T-cell malignancies exhibit resistance to the standard therapy, CHOP, which results in limited anti-tumor activity and poor prognosis. This highlights a significant unmet medical need for novel treatment strategies. Given that CD5 is ubiquitously expressed on most T-cell malignancies, it represents ...

Introduction: Canine lymphoma (CNL) is similar to the human disease and accounts for ~6% of all cancers in dogs. The majority of CNL are of B-cell origin (B-CNL), although a significant proportion are T-cell lymphoma (T-CNL; ~28%). Standard of care chemotherapy is effective against B-CNL but la...

Introduction:A patient with mycosis fungoides (MF) harboring a PCM1-JAK2 fusion experienced a durable response to ruxolitinib before developing resistance. Here, we detail the case and the molecular profiling of her tumors before and after ruxolitinib resistance.Methods:Mutational profiling was perf...

R/R PTCL patients require novel, lineage-specific therapies with manageable toxicity to bridge them to HSCT. A prior phase I/II study of duvelisib/romidepsin(D/R) reported ORR of 58% and CRR of 42% with reduced grade 3-4 transaminitis(14%) vs duv-monotherapy. We report real-world outcomes on a multi...

Introduction:This abstract focuses on the activity of BI-1808, a monoclonal antibody targeting TNFR2, in patients with cutaneous T-cell lymphoma (CTCL). TNFR2 overexpression on malignant CD4+CD26- T-cells points to its possible implication in the pathogenesis of CTCL. BI-1808 inhibits the interactio...

ITK is expressed in T cells and NK cells and is involved in multiple signaling pathways including T cell receptor activation, differentiation of naïve helper T cells and FAS mediated activation-induced cell death. Selective knock-out or inhibition of ITK results in Th1 skewing and enhancement of T ...